This initiative provides early stage translational support to identify and characterize potential therapeutic candidates and combination products for HLBS diseases and disorders. It aims to transition basic science discoveries into viable diagnostic and therapeutic candidates cleared for human testing, fostering translational researchers skilled in product development and entrepreneurship. Clinical trials are not allowed under this funding.
Eligible applicants include small businesses, various government entities, institutions of higher education, nonprofits, and tribal organizations. Specific eligibility details are provided in the full announcement.
